Michael Borowitz

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]
    Elizabeth A Raetz
    New York University School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, 160 E 32nd St, New York, NY 10016, USA
    J Clin Oncol 26:3971-8. 2008
  2. ncbi Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry
    Michael J Borowitz
    Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cytometry B Clin Cytom 78:211-30. 2010
  3. ncbi Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
    Michael J Borowitz
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Blood 111:5477-85. 2008
  4. ncbi Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group
    Michael J Borowitz
    Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cytometry B Clin Cytom 68:18-24. 2005
  5. ncbi Epstein-Barr virus-associated central nervous system lymphoproliferative disease in a patient with acquired immunodeficiency syndrome responsive to highly active antiretroviral therapy
    Dennis Z Kuo
    Division of General Pediatrics and Adolescent Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Infect Dis 46:1476-8. 2008
  6. ncbi Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma
    Margaret L Gulley
    Department of Pathology, University of Texas Health Science Center at San Antonio, USA
    Am J Clin Pathol 117:259-67. 2002
  7. ncbi Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method
    I Ming Chen
    Department of Pathology, University of New Mexico HSC and Cancer Research and Treatment Center, Albuquerque, NM USA
    Br J Haematol 135:358-61. 2006
  8. ncbi Hematological manifestations of nephropathic cystinosis
    Ashkan Emadi
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Acta Haematol 119:169-72. 2008
  9. ncbi Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
    Deepa Bhojwani
    New York University (NYU) Cancer Institute and Division of Pediatric Hematology/Oncology, NY 10016, USA
    Blood 108:711-7. 2006
  10. ncbi Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study
    Elizabeth A Raetz
    Department of Pediatrics, New York University, School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, New York, NY 10016, USA
    J Clin Oncol 26:3756-62. 2008

Research Grants

  1. Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
    Michael Borowitz; Fiscal Year: 2009
  2. Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
    Michael Borowitz; Fiscal Year: 2007
  3. Minimal Residual Disease in Childhood ALL in Relapse
    Michael Borowitz; Fiscal Year: 2006
  4. RESIDUAL DISEASE DETECTION IN ALL USING FLOW CYTOMETRY
    Michael Borowitz; Fiscal Year: 2004
  5. Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
    Michael J Borowitz; Fiscal Year: 2010

Collaborators

Detail Information

Publications16

  1. ncbi Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]
    Elizabeth A Raetz
    New York University School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, 160 E 32nd St, New York, NY 10016, USA
    J Clin Oncol 26:3971-8. 2008
    ..The goal of the Children's Oncology Group (COG) AALL01P2 study was to develop a safe and active chemotherapy reinduction platform, which could be used to evaluate novel agents in future trials...
  2. ncbi Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry
    Michael J Borowitz
    Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cytometry B Clin Cytom 78:211-30. 2010
    ....
  3. ncbi Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
    Michael J Borowitz
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Blood 111:5477-85. 2008
    ..These studies are registered at www.clinicaltrials.gov as NCT00005585, NCT00005596, and NCT00005603...
  4. ncbi Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group
    Michael J Borowitz
    Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cytometry B Clin Cytom 68:18-24. 2005
    ..However, little is known about how phenotypic shifts between diagnosis and relapse affect MRD detection in childhood acute lymphoid leukemia (ALL)...
  5. ncbi Epstein-Barr virus-associated central nervous system lymphoproliferative disease in a patient with acquired immunodeficiency syndrome responsive to highly active antiretroviral therapy
    Dennis Z Kuo
    Division of General Pediatrics and Adolescent Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Infect Dis 46:1476-8. 2008
    ..Our experience highlights the importance of biopsy in evaluating multifocal radiographic CNS lesions and the central role of HAART in treating AIDS-related CNS disease...
  6. ncbi Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma
    Margaret L Gulley
    Department of Pathology, University of Texas Health Science Center at San Antonio, USA
    Am J Clin Pathol 117:259-67. 2002
    ..EBER and LMP1 assays in combination are more effective than either assay alone for identifying EBV-related Hodgkin lymphoma...
  7. ncbi Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method
    I Ming Chen
    Department of Pathology, University of New Mexico HSC and Cancer Research and Treatment Center, Albuquerque, NM USA
    Br J Haematol 135:358-61. 2006
    ..The data presented here indicate that a significant number of low-level apparent Q-PCR positive results may be spurious or non-specific in nature, requiring additional technical manoeuvres for confirmation of true positive cases...
  8. ncbi Hematological manifestations of nephropathic cystinosis
    Ashkan Emadi
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Acta Haematol 119:169-72. 2008
    ....
  9. ncbi Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
    Deepa Bhojwani
    New York University (NYU) Cancer Institute and Division of Pediatric Hematology/Oncology, NY 10016, USA
    Blood 108:711-7. 2006
    ..These results suggest that early-relapse results from the emergence of a related clone, characterized by the up-regulation of genes mediating cell proliferation. In contrast, late relapse appears to be mediated by diverse pathways...
  10. ncbi Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study
    Elizabeth A Raetz
    Department of Pediatrics, New York University, School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, New York, NY 10016, USA
    J Clin Oncol 26:3756-62. 2008
    ....
  11. ncbi Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma
    Shiyong Li
    Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Clin Pathol 118:229-34. 2002
    ..SIg-negative B-cell lymphomas are rare. Complete absence of SIg light chain expression in a mature B cell proliferation can be used as a surrogate marker to help diagnose peripheral B-cell lymphoma...
  12. ncbi High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 11:93-100. 2005
    ..These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission should be offered BMT if it is otherwise indicated...
  13. ncbi Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia
    Christopher J Gamper
    Division of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Pediatr Blood Cancer 50:1072-5. 2008
    ....
  14. ncbi The usefulness of CD71 expression by flow cytometry for differentiating indolent from aggressive CD10+ B-cell lymphomas
    Julie M Wu
    Department of Pathology, Johns Hopkins Medical, Institutions, Baltimore, MD, USA
    Am J Clin Pathol 126:39-46. 2006
    ..Sensitivity and specificity are limited owing to inability to identify FL3. In ROC analysis, a high value for CD71i can identify BL and LBCL with a high degree of certainty...
  15. ncbi Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
    Kirk R Schultz
    Children s Oncology Group, Department of Pediatrics, BC Children s Hospital, University of British Columbia, Vancouver, Canada
    Blood 109:926-35. 2007
    ....
  16. ncbi Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group
    Stella M Davies
    Department of Pediatrics, Cincinnati Children s Hospital and Medical Center, OH 45230, USA
    Blood 111:2984-90. 2008
    ..009, logistic regression), when comparing "best" and "worst" risk groups. These data are consistent with growing evidence that both acquired and host genetics influence response to cancer therapy...

Research Grants10

  1. Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
    Michael Borowitz; Fiscal Year: 2009
    ..These studies will give us a better understanding of how to use prognostic information in treating children with ALL, and bring us closer to our goal of curing the maximum number of children with ALL with the least toxic therapy. ..
  2. Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
    Michael Borowitz; Fiscal Year: 2007
    ..These studies will give us a better understanding of how to use prognostic information in treating children with ALL, and bring us closer to our goal of curing the maximum number of children with ALL with the least toxic therapy. ..
  3. Minimal Residual Disease in Childhood ALL in Relapse
    Michael Borowitz; Fiscal Year: 2006
    ..We will also be able to extend these studies to other situations where we can use MRD as a rapid means to compare therapies. ..
  4. RESIDUAL DISEASE DETECTION IN ALL USING FLOW CYTOMETRY
    Michael Borowitz; Fiscal Year: 2004
    ....
  5. Minimal Residual Disease in Pediatric ALL in Relation to Other Prognostic Factors
    Michael J Borowitz; Fiscal Year: 2010
    ..These studies will give us a better understanding of how to use prognostic information in treating children with ALL, and bring us closer to our goal of curing the maximum number of children with ALL with the least toxic therapy. ..